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Objectives. This study examined the effect of metabolic distur-
bances, hemostatic function, coronary
artery disease severity and
left ventricular function on the long-term
prognosis after myocar-
dial infarction in men <45 years old
.
. Heavy smoking; dysllpoproteinemias
involving
very low density lipoprotein
(VLDL), low density lipoprotein
(LDL) and high density lipoprotein (HDL)
; a family history of
premature coronary artery disease; hyperinsulinemic
responses to
oral and Intravenous glucose challenges
; and defective fibrinolytic
function characterize the young postinfarction patient, but
the
Influence of these features on the long-teem prognosis is virtually
unknown.
M . Measurements of hemostatic function
and metabolic
and a
phic indicators of risk were Included in a prospective
cohort study of variables predictive of reinfarction, cardiac death and
major coronary events within 6 to 9 years in 1 unselected nondia .
belie men with a first myocardial infarction before age 45 years.
Myocardial infarction at a young age is by definition an uncom-
mon condition and for the most part afflicts men (1) . Angio-
graphic studies (2-5) have demonstrated that coronary morphol-
ogy is heterogeneous in young postinfarction patients,
and, in
particular, a significant proportion of these patients have an
entirely normal coronary angiogram or apparently nonatheroscle-
rotic lesions. Single-vessel disease is also considerably more
prevalent in young postinfarction patients than in other uns-
elected postinfarction patients . These observations raised specu-
lation concerning basic differences
in etiologic factors and patho-
genic mechanisms
. We studied (6-9) young male postinfarction
patients in our unit and identified a risk factor profile comprising
heavy smoking
; dyslipoproteinemias involving very low density
lipoprotein (VLDL), tow density lipoprotein (LDL) and high
density lipoprotein (HDL); a family history of premature coro-
nary artery disease
; hyperinsulinemic responses to oral
and
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Results. During follow-up, 20 patients had sudden cardiac
death, and 53 had a major coronary event (reinfarction, sudden
cardiac death, bypass surgery or intervention by catheterization) .
In multivariate analysis, VLDL and global coronary atheroscle-
rosis score predicted reinfarction ; plasma plasminogen activator
inhibitor-1 (PAI-1) activity and global coronary stenosis score
predicted cardiac death; and VLDL triglyceride levels, global
coronary atherosclerosis score and age predicted any major
coronary event.
Conclusions. This prospective cohort study shows that hyper-
triglyceridemia, impaired fibrinolytic capacity secondary to
plasma PAW activity elevation and extensive coronary artery
disease increase the risk of recurrences in men with a first
myocardial infarction before age 45 and contribute to the rela-
tively poor long-term prognosis in this patient group .
(J Am Coll Cardiol 1994;24:592-9)
intravenous glucose challenges ; and defective fibrinolytic func-
tion. Dyslipoproteinemias were found in 75% of the male pa-
tients, and disorders of triglyceride-rich lipepitein metabolism
predominated over hyperchoiesterolemias . Manifest diabetes
mellitus or decreased oral glucose tolerance was present in -40%
of patients. Furthermore, angiographic studies (10-12) indicated
that the plasma concentrations of dense LDL and HDL,,,, the
largest HDL particle subspecies, are correlated most closely with
global severity and rate of progression of coronary lesions (10-
12) .
The long-term prognosis of young men with myocardial
infarction appears to be fairly good in absolute terms; however,
compared with healthy contemporaries, the mortality rate is
markedly high (13-15). A recent longitudinal cohort study (16)
of young men who survived a first myocardial infarction
showed that decreased fibrinolytic activity, mainly due to
elevated plasma plasminogen activator inhibitor-1 (PAW)
activity, dyslipoproteinemia involving VLDL and HDL, exten-
sive coronary atherosclerosis and poor left ventricular function
are independently related to reinfarction within 3 years of the
primary event . By contrast, knowledge of the determinants of
long-term prognosis is sparse.
The present study examined the relations between distur-
bances of lipoprotein and glucose metabolism, fibrinolytic
function, coronary artery disease severity, left ventricular func-
tion and major cardiac events in unselected men <45 years old
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with a first myocardial infarction . It was hypothesized that
biochemical disturbances would particularly influence the clin-
ical course of this patient category, and .-mphasis was placed
on elucidating the prognostic impact of hype f I riglyce ridem ia,
decreased oral glucose tolerance and defective fibrinolytic
function due to elevated plasma levels of PAI-1, concordant
abnormalities commonly associated with premature coronary
artery disease and myocardial infarction at a young age .
Methods
Patients. Between May 1980 and May 1983, 151 male
patients <45 years old survived a confirmed myocardial infarc-
tion in the I I hospitals with a coronary care unit within
Stockholm County . Briefly, myocardial infarction was diag-
nosed when at least two of the following three criteria were
fulfilled (17): 1) central chest pain >15 min in duration ; 2) two
consecutive determinations of serum aspartate aminotransfer-
ase concentration showing elevated values, with a maximum
occurring -24 h after the estimated onset of infarction, combined
with a less pronounced increase or lack of increase of serum
alanin arninotransferase level; and 3) electrocardiographic (ECG)
series with development of pathologic 0 waves or development or
disappearance of localized ST segment elevation followed by T
wave inversion in two or more of 12 routine ECG leads . Survivors
were subsequently referred to the cardiovascular unit at one of
the hospitals for further metabolic, hemostatic and cardiologic
investigations . A total of 108 nondiabetic patients (72%) partici-
pated in the present follow-up study (mean J±SDJ age 40 .3 ± 3.5
years, range 23 to 44 years). Of the remaining 43 patients, 2 died
in the early postinfarction period before the baseline evaluation ;
4 declined to participate ; and for technical reasons glucose
loading tests were not performed in 7 participants . A total of 16
patients dropped out of the study at an early stage or were lost to
follow-up because of emigration. Five patients were excluded
from the study group because of previous myocardial infarction,
seven because of manifest diabetes and two because of severe
renal disease.
Control subjects. To enable identification of metabolic and
hemostatic disturbances in the patient group, a total of 116
age-matched men from the same residence area were ran-
domly selected and examined along with the patients . None of
the control subjects had a history suggestive of angina pectoris
or ECG signs indicative of coronary artery disease (Minnesota
Codes 4.1 and 4.2) .
Clinical procedures. Full details of the principles for re-
cruitment to the study, general treatment of the patients and
the laboratory methods used have been described elsewhere
(7,16). In the patients, all metabolic, hemostatic and cardio-
logic investigations were done 3 to 6 months after the infarc-
tion. Clinical data were abstracted from the medical records
aquired during admission to the referring coronary care units.
Complementary information concerning smoking habits and
other life-style characteristics -was obtained by a structured
interview and self-administered questionnaire at the time of
the baseline investigation, at 3 years after the primary event
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and at the end of the follow-up period. Lipid-lowering medi-
cation (cholestyraminc alone or in combination with nicotinic
acid) was prescribed in six patients with heterozygous mono-
genic hypercholesterolemia . Beta-adrenergic blocking agents
were taken by 69 of the patients (64%) at the time of the
metabolic and hemostatic evaluation according to the policy of
the referring units . Unselective agents were substituted with
cardioselective metoprolol or atenolol at the first visit to the
research unit, in view of subsequent metabolic investigations .
Coronary artery bypass graft surgery was performed only in
patients with stenosis of the left main coronary artery or in the
presence of disabling angina pectoris despite medication .
Angiographic multiple-vessel disease in symptomless or mildly
symptomatic patients was not regarded as an indication for
surgical intervention .
Biochemical analyses . Serum lipoprotein levels were de-
termined by a combination of preparative ultracentrifugation
and precipitation of apolipoprotcin B-containing lipoproteins,
followed by lipid analysis in the major lipoprotein fractions
(18). In addition, the HDL subclass HDL
3
was obtained as a
bottom fraction in which cholesterol levels were determined
after preparative ultracentrifugation in a fixed-angle rotor at a
density of 1 .125 kg/liter (19) . The HDL2 cholesterol concen-
tration was calculated as the difference between total HDL and
HDL
3
. Lipoprotein phenotyping according to the World
Health Organization (WHO) classification (20) was based on
lipoprotein quantification and agarose gel lipoprotein electro-
phoresis (21). The cutoff limits of the different lipoprotein
phenotypes were set to the 90th percentile of VLDL triglycer-
ide and LDL cholesterol values in age- and gender-matched
random control subjects. Lipoprotein(a) was measured in
serum samples by an enzyme-linked immunosorbent assay
(ELISA) utilizing sheep polyclonal antibodies against purified
human lipoprotein(a) ITint Elize Lp(a) . Biopool, UnieA, Swe-
den). Serum apolipoprotein B concentrations were determined
from frozen samples (-80°C) with an ELISA .
Oral glucose tolerance was assessed after ingestion of glucose
in a dose of 1.75 g/kg body weight using criteria adapted from
Reaven et al . (22) . Glucose was measured in whole blood by the
glucose oxidase method (23) and plasma insulin by a double
antibody radioimmunoassay (24) . Plasma insulin response (incre-
mental insulin) was calculated as the insulin area above the
fasting level. A glucose infusion test was also performed according
to Cerasi and Luft (25). The early insulin response was calculated
as the insulin area above fasting level between 0 and 10 min and
the late insulin response as the corresponding area between 10
and 60 min of the infusion .
Procedures for blood sampling, preparation of citrated
piasma for hemostatic tests and calibration of assays have been
described in detail elsewhere (16) . Plasma fibrinogen concen-
tration was measured by means of a polymerization test (26) .
PAI-1, the rapid inhibitor of the tissue-type plasminogen
activator, was determined as plasma PAI-1 activity (27) using a
commercially available kit (Biopool) . Factor VIII was measured
with a two-stage thrombin generation assay (28) and von Will-
ebrand factor antigen with quantitative electroimmunoassay (29) .
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Antithrombin activity was determined by a chromogenic peptide
substrate method (30) .
Coronary and left ventricular angiography . Coronary an-
giography was performed by the percutaneous transfemoral
technique and recorded on 35-mm cine film with the aid of
cesium iodide-activated image intensifiers . Angiograms were
obtained both before and after administration of sublingual
nitroglycerin
. Cine films were processed in the conventional
manner and viewed by means of a Tagarno projector (Horsens,
Denmark). Evaluations were performed in blinded manner
.
The presence and severity of both diffuse atherosclerosis and
distinct stenoses were determined by means of separate clas-
sification systems in 15 proximal coronary artery segments
(31). In the global coronary atherosclerosis score, points were
assigned for both extension of atherosclerotic lesions and
plaque size in each segment . The scores for extension and
plaque size were multiplied to produce a segmental athero-
sclerosis severity score. The global coronary atherosclerosis
score was then obtained by dividing the sum of all segmental
atherosclerosis scores by the number of segments accessible to
evaluation, The estimate of global coronary atherosclerosis
obtained by means of this scoring system included both diffuse
lesions and distinct hcmodynamically significant stenoses. The
global coronary artery stenosis score was calculated as the
global atherosclerosis score but included only lesions that
reduced the lumen diameter ?25%. Patients were also allo-
cated to traditional coronary artery disease categories accord-
ing to the number of major coronary arteries with stenosis of
the lumen diameter >_50% in any projection (31) . Left ven-
tricular ejection fraction was calculated by the area-length
method (32) .
Follow-up and definition of clinical end points. After dis-
charge from the referring units, all patients were seen by one
of the authors within 2 weeks and then regularly during the
entire follow-up period, which was terminated on May 1, 1989
(follow-up time range 6 to 9 years) . No patient was lost to
follow-up with respect to survival, occurrence of reinfarction or
need forcoronary artery bypass graft surgery . Criteria for nonfa-
tal reinfarction were identical to those for primary infarction (17) .
The reinfarction was defined as early if it occurred within 3 years
after the index infarction and late if it occurred thereafter. A fatal
reinfarction was diagnosed according to criteria previously pub-
lished in detail (16) . Sudden cardiac death was diagnosed in
patients in whom no extracardiac or cardiac cause of death could
be detected. A major coronary event was defined as either cardiac
death, nonfatal reinfarction or need for coronary artery bypass or
percutaneous transluminal coronary angioplasty .
Statistical analysis. Coefficients of skewness and kurtosis
were calculated to test deviations from a normal distribution,
and logarithmic transformation was performed on the individ-
ual values of skewed variables before statistical computations
and significance testing. Group differences in continuous vari-
ables were determined by one-way analysis of variance . The
Scheffd F test was used to identify differences among the
groups when the overall F statistics was significant . Distribu-
tions of categoric data were compared by means of the chi-square
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test with the Yates correction. The prognostic power of different
clinical, metabolic and hemostatic variables was determined with
the use of the Cox proportional-hazards survival analysis with
covariates (BMDP2L). After univariate analysis of the relations
of all variables to cardiac end points, a stepwise selection process
was adopted to identify a subset of variables that were associated
significantly and independently with the time to occurrence of a
cardiac event . Variables were entered (p < 0.10) or removed
(p > 0.15) from the equation on the basis of the maximal partial
likelihood ratio. The impart of traditional angiographic coronary
artery disease categories on the risk of futur' cardiac end points
was also determined by product-limit survival analysis and
Mantel-Cox statistics.
Ethical considerations. The study protocol was approved
by the local ethics committee . All subjects gave their informed
consent to participate in the study.
Results
Baseline clinical and metabolic characteristics (Table 1),
As a group the patients were hyperlipidemic, and hypertriglyc-
eridemic phenotypes (hyperlipoproteinemias types Ilb, III and
IV) tended to predominate over hypercholesterolemia (type
Ila hyperlipoproteinemia) . Approximately 65% of patients had
borderline or definitely decreased oral glucose tolerance, and a
similar proportion had a high insulin response to oral glucose
challenge. Angiography showed multiple-vessel disease in 60%
of patients . The majority of the patients had normal or only
slightly reduced left ventricular performance (ejection fraction
0.58 -_" 0 .17).
Clinical outcome (Fig 1) . In the course of follow-up, 39
patients (36%) had a reinfarction : early (e3 years) in 15, late
(>3 years) in 24 (Fig 1, left), fatal in 17 and nonfatal in 22 .
Three more patients died in the course of follow-up, presum-
ably due to arrythmia, and were categorized as having sudden
cardiac death (Fig. 1, middle). Aortocoronary bypass graft
surgery or coronary angioplasty was performed in 11 patients .
In all, 53 patients (-50%) had a major coronary event, defined
as either cardiac death, nonfatal reinfarction or surgical or
catheter intervention, during the follow-up period (Fig. 1,
right).
Lipoprotein metabolism (Table 2) . By univariate analysis
VLDL cholesterol concentration was significantly higher in
patients with an early reinfarction, whereas apolipoprotein B
level was distinctly higher in those with a late reinfarction . The
HDL fraction did not discriminate between the groups, nor did
lipoprotein(a) . Serum apolipoprotein B concentration was
higher in patients with any major coronary event, whereas no
lipoprotein variable deviated significantly in those with cardiac
death during follow-up .
Glucose and insulin homeostasis. Glucose and insulin
homeostasis could not discriminate between patient sub-
groups. There was a tendency to higher glucose areas under
the curve during the oral glucose tolerance test and to higher
late insulin responses during the glucose infusion test in the
patients with an early reinfarction (data not shown) .
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Table 1.
Clinical Characteristics of Study Group at Baseline
(470-30,215)
	
(670-26,255)
*Unpaired two-tailed t test for continuous and chi-square test for categoric variables . i Stopped smoking before or at
the time of infarction . tPresent if antihypertensive medication had been instituted before the infarction or if blood
pressure was > 160 mm Hg systolic or 95 mm fig diastolic, or both, on repeated measurements . §Performed in 103 of the
108 patients
. Data presented are mean value ± SD, number of patients or geometric mean value (range). CAD
coronary artery disease
: HDL = high density lipoprotein ; LDL = low density lipoprotein; WIT = oral glucose
tolerance test, performed in 1(1(1 control subjects : VLDL = very low density lipoprotein.
Hemostatic function (Table 3) . High plasma PAM activity
was associated with early reinfarction but did not appear to
affect the risk of late reinfarction . Fibrinogen, Factor VIII, von
Willebrand factor antigen and antithrombin levels did not
differ between patient groups. Plasma PAM activity was also
higher in patients with cardiac death or any major coronary
event.
Figure 1. Cumulative proportion of
patients (%) with reinfarction, cardiac
death or any major coronary event
during the follow-up period .
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Angiographic findings. Patients with early reinfarction had
strikingly higher coronary atherosclerosis (2.08 ± 1.07) and
stenosis (2.60 ± 1 .54) scores compared with patients with a late
reinfarction (1 .65 ± 0.96, p = NS; 1.47 ± 0.96, p < 0 .01,
respectively) or patients with an uneventful course (1 .23 ±
1.04, p < 0.05 ; 1 .35 ± t).93, p < 0.001, respectively) . Signifi-
cantly higher global coronary atherosclerosis and stenosis
100
ANY MAJOR
-100
60
CORONARY EVENT . 80
60 60
40
40
20
20
Patients
(n = 108)
Control Subjects
(n = 116)
p
Value*
Age (yr) 40.3 ± 3
.5 39.9 ± 3 .9
NS
Smoking habit
Never smoked 4 41
Ex-smoker( 57
30
< 0-001
Current smoker
47 45
Hypertension# 23
12 < 0
.001
Cholesterol (mmol/liter)
VLDL 0 .90
0.42
< 0 .001
(0.15-4
.42) (0 .04-5 .26)
LDL 5 .01 ± 1 .18
3
.97 ± 0
.92 < 0 .001
HDL
1 .12±0.22 1 .45±0.38
<0.001
Triglycerides (mmol/liter)
VLDL
( .54 0 .69 < 0
.01)1
(0 .34-8.96) (d).118-10 .81)
LDL 0.46
0 .32 < 0
.(N)1
(0
.17-1 .10) (0.19-0.73)
HDL 0.15 0
.14 NS
(0.07-0
.41) (0 .05--0.26)
WIT
Normal
38 59
Borderline 35
31 < 0 .001
Decreased 35 10
OGTT incremental insulin
6,538 4,255 < 0 .001
CAD category§
Insignificant 6
Single vessel 35
Double vessel 38
Triple vessel 24
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scores also characterized patients who died (2
.14 ± 0 .97 vs.
1
.30 ± 1.03, p < 0 .01 ; 2.56 ± 1 .41 vs . 1 .35 ± 0.93, p < 0
.001,
respectively) or had any major coronary event during follow-up
(1.82 ± 1.02 vs . 1 .08 ± 1 .00, p < 0.001 ; 1 .83 ± 1
.30 vs . 1 .29
0.84, p < 0.05, respectively) . In contrast, no statistically
significant differences were present in left ventricular ejection
fraction between patients with a reinfarction and those with an
uneventful course (data not shown). However, patients who
had a late reinfarction had a higher ejection fraction than those
who had an early reinfarction (0
.66 ± 0.14 vs. 0.50 ± 0 .18,
respectively, p < 0.05). Furthermore, left ventricular ejection
fraction was lower in patients who died during follow-up (0 .48
~° 0.17 vs. 0.60 ± 0.16, respectively, p < 0 .01).
Predictors of reinfarction, cardiac death and a major coro-
nary event. Age; VLDL triglyceride, LDL and HDL cholesterol
and apolipoprotein B concentrations ; coronary atherosclerosis
and stenosis scores; left ventricular ejection fraction
; and PAW
activity were included in building the Cos proportional hazards
models . Predictors were identified for reinfarction, cardiac death
and a major coronary event (nonfatal reinfarction, cardiac death
and need for coronary artery bypass graft surgery or coronary
angioplasty).
In univariate analysis the serum concentrations of VLDL
triglycerides, LDL and HDL cholesterol and apolipoprotein B
were found to relate significantly to reinfarction, along with
plasma PAI-I activity and global coronary atherosclerosis and
stenosis scores (Table 4) . Global coronary atherosclerosis
score and VLDL triglyceride concentration were subsequently
selected for the final model in the multivariate analysis . The
corresponding predictors , f cardiac death were VLDL triglyc-
eride and HDL cholesterol concentrations, both coronary
scores and plasma PAW activity (Table 4) . The coronary
stenosis score and plasma PAI-1 activity were found to remain
significant and independent predictors of cardiac death in the
multivariate analysis
. With respect to predicting any major
coronary event, age, VLDL triglyceride and HDL cholesterol
concentrations, the two coronary scores and plasma PAI-1
activity contributed significantly in univariate analysis, whereas
global coronary atherosclerosis score, VLDL triglyceride con-
centration and age, in that order, were included in the final
multivariate model (Table 4). Notably, LDL and HDL choles-
terol and apolipoprotein B concentrations and left ventricular
ejection fraction were not found to add independent prognos-
tic information with respect to any of the end points studied .
The impact of the traditional coronary artery disease cate-
gories (zero to triple-vessel disease according to the number of
major coronary arteries with lumen diameter stenosis >50% in
any projection) on the risk of future cardiac end points was
also determined . The risk of a reinfarction was significantly
higher in patients with multiple-vessel disease on the baseline
coronary angiogram than those with zero or single-vessel
disease (p = 0.038)
. Multiple-vessel disease also tended to
increase the risk of cardiac death (p = 0
.079), whereas no
distinct relation was found with the major coronary event end
point (p = 0.241) .
JACC Vol. 24, No
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Table 3
. Hemostatic Function in Patients With and Without a Cardiac Event
*Analysis of variance for differences between patients with and without an
early or late reinfarction
. tUnpaired two-tailed (
test of differences between patients with
and without event . *p < 0.05 compared with patients without reinfarction
. Values presented are mean value i SD or geometric mean value (range)
. PAI-I
plasminogen activator inhibitor-I ; vWF = von Willebrand factor
.
Discussion
Although limited in size, this prospective cohort study
shows that hypertriglyceridernia, impaired filrinolylic capacity
secondary to plasma PAI-I activity elevation and extensive
coronary artery disease increase the risk of recurrences in
men <45 years of age with a first myocardial infarction and
contribute to the relatively poor long-term prognosis in this
patient group. This study is unique in that an extensive
biochemical evaluation was combined with angiographic as-
sessment of coronary artery disease severity in a population-
based patient group with nearly complete available follow-up
data. Both the angiographic and most biochemical variables
appeared to primarily predict the early events. However,
apolipoprotein B concentration, a direct reflection of the
number of circulating atherogenic lipoprotein particles, was
higher in patients who had a late reinfarction . Accordingly,
atherogenic and thrombotic mechanisms appear to act in
concert in predisposing to recurrences. It is notable that a
previous angiographic study (10) documented the progression
of coronary atherosclerosis in 87% of young postinfarction
patients, a majority of whom (58%) had developed multiple-
vessel disease -5 years after the primary event . An increase in
the number of major coronary arteries with hemodynamically
Table 4. Prediction of Reinfarction, Cardiac Death or Major Coronary Event by Cox Proportional Hazards Survival Analysis
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significant stenosis was found in 40% of these patients . Pro-
gression of coronary artery disease is thus a likely major
mechanism underlying the majority of late cardiac events in
the present study. However, the present findings, as well as
earlier data from our group (6,16), indicate that elevated
plasma PAM activity, resulting in reduced fibrinolytic capac-
ity, may be -important in the pathogenesis of myocardial
infarction, particularly in patients with hypertriglyceridemia .
Role of hypertriglyceridemia . Hypertriglyceridemia was by
far the most common lipoprotein disturbance among the
young postinfarction patients . There are several tentative
atherogenic mechanisms operating in hype rtriglyceridemic pa-
tients (33) . In addition to the direct effects of triglyceride-rich
lipoproteins on the arterial wall, the hypertriglyceridenic state
has also been shown to act indirectly by influencing the
metabolism and composition of intermediate density lipopro-
tein (IDL), LDL and HDL . In particular, a small, dense LDL
pattern is frequently present in the hypertriglyceridemic pa-
tient . There is also an abundance of data (33) indicating that
hypertriglyceridemic subjects have delayed clearance of post-
prandial lipoproteins, which may be taken up by arterial wall
macrophages. Finally, consistent epidemiologic, clinical and
experimental evidence exist (34) that hypertriglyceridemia
Chi-sq = chi-square analysis ; other abbreviations as in Tables 1 to 3 .
Reinfarction
Cardiac Death
Any Major Coronary Event
No
(n = 69)
Early
(n = 15)
Late
(n = 24)
p
Value
No
(n = 88)
Yes
in 20)
p
Value',
No
(n 55)
Yes
(n 53)
p
Valuet
Fibrinogen (g/liter) 3 .6 ± It 3 .6 ± 1 .4
3 .5 ±
1
.0 NS 3.5±0 .9
3.9±1 .4 NS
3.5 0.9 3.7±1 .2
NS
Factor VIII (%)
103 ± 32 117 ± 22 104 ± 33
NS 104 :± 32 113 27
NS 104 35
107 28 NS
vWF antigen (%) 107 ± 40 118 ± 45
115 ± 56 NS
109 42 120 55 NS
111 43 111 47
NS
Antithrombin
104 ± 10 108 ± 10 104 ± 10 NS
104 10 107 12
NS 104 :L 11
106 10 NS
PAI-I (IJiml)
11(0-65) 25(9-65)$ 13(0-45) < 0.05
11(0-65) 22(8-65)
< 0.05 11(0-50) 15(0-65)
NS
Reinfarction
Cardiac Death Major Coronary Event
No Variables
Entered
Final
Model
No Variables
Entered
Final
Model
No Variables
Entered
Final
Model
Covariate
p
Chi-sq Value
Global
Chi-sq
p
Value
p
Chi-sq Value
Global
Chi-sq
p
Value
p
Chi-sq Value
Global
Chi-sq
p
Valde
Age 1 .16 0 .281 0 .05
0.819 5 .80 0.016 25 .12 < 0 .001
VLDL Tg 8 .17 0 .004 20 .98 < 0 .001 6.26
0.012 10 .O.3 0 .002 22 .80
-0,001
LDL Chol
3.87 0 .049
0.29 0.589 0.53
0.467
HDL Chol 4 .48 0 .034 7 .29
0.007 4 .98 0.026
Apo B 6 .30 0 .012
1 .53 0.216 3 .54 0 .060
Atherosclerosis score 13 .73 < 0 .001
14
.62
< 0.001 9.96 0.002
14 .29 < 0 .001 15 .24 < 0.001
Stenosis score
11 .51 < 0 .001 14.61
< 0.001 18 .08 < 0.001 11 .18 0 .001
Ejection fraction 0 .00 0 .955
4 .70 0.030
0 .03 0.864
PAP1
4 .85 0 .004 7 .73 0.005
19 .53 < 0A1 6 .48 0.011
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represents a procoagulant state involving derangements of
both blood coagulation and fibrinolysis .
Glucose and insulin homeostasis. Impaired glucose toler-
ance and hyperinsulinemic responses to oral glucose challenge
and a glucose infusion test were common among the patients in
this study but were not indicated to have direct prognostic
importance. However, plasma insulin levels are known to
influence lipoprotein composition and lipoprotein receptor
interactions (35). These effects are accounted for mainly by
stimulation of VLDL triglyceride production rate and subse-
quent lipid transfer during the ensuing hype rtriglyceridemic
state (,36) . In the past several years a number of studies (37)
have focused on the clustering of metabolic disturbances
associated with insulin resistance : a particular lipoprotein
profile (high triglyceride and low HDL cholesterol concentra-
tions), glucose intolerance and hyperinsulinemia . Recently, it
was proposed (38) that plasma insulin is the major physiologic
regulator of PAW activity and is secondary to that of fibrino-
lytic function. In the young postinfarction patients, high fasting
and postload insulin levels were associated with increased
VLDL triglyceride and decreased HDL cholesterol concentra-
tions, as well as with elevated plasma PAW activity . It is thus
possible that impaired glucose tolerance and hyperinsulinemia
exerted an indirect adverse influence on the prognosis of some
patients in the present study through effects on the levels of
triglyceride-rich lipoproteins and PAW activity .
Coronary artery disease severity . Numerous studies (2-5)
pointed out the heterogeneous angiographic appearance of the
coronary arteries in young postinfarction patients . The present
study indicates that classification of the coronary angiogram
according to the number of major vessels with hemodynami-
cally significant stenoses and calculation of summary estimates
of global coronary atherosclerosis and stenoses are of great
prognostic importance. Because such detailed information is
not accessible with sufficient accuracy from noninvasive inves-
tigations, routine coronary angiography seems highly war-
ranted as a prognostic tool in these patients .
Conclusions. Metabolic and hemostatic disturbances tend
to be somewhat ignored in the clinical evaluation of the
postinfarction patient, and our results suggest that cardiolo-
gists should take them more seriously . According to the
present data, increased triglyceride concentrations, an often
neglected and much-debated coronary risk indicator, should he
attended to, at least in young postinfarction patients, along
with the generally accepted lipoprotein risk factors of LDL and
HDL cholesterol concentrations. In addition, elevated plasma
PAl-I activity ought now to be recognized as a useful marker
of increased risk of recurrences . Finally, it should be empha-
sized that our data may not be valid for other age groups, for
women and for patients with premature coronary artery dis-
ease but no previous myocardial infarction. The limited sample
size also prevented identification of factors with a moderate
effect on prognosis, and the risk of multiple comparisons
should not be disregarded. These restrictions notwithstanding,
young survivors of myocardial infarction represent a poignant
challenge to basic and clinical research on atherogenic mech-
JACC Vol . 24. No. 3
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anisms and factors predisposing to and precipitating coronary
thrombosis .
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